Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy
To evaluate the efficacy, safety, and immunogenicity of PEG-G-CSF Injection (Kexing Biopharmaceutical Co., Ltd.) for the prevention of neutropenia after chemotherapy, using the PEG-G-CSF Injection ( Neulasta®, Amgen Europe B.V.) as a positive control.
Neutropenia, Chemotherapy-Induced Febrile|Breast Neoplasm Female
DRUG: PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)|DRUG: PEG-G-CSF injection (Neulasta®，Amgen Europe B.V.)
Duration of 4th degree neutropenia during chemotherapy cycle 1, At the end of Cycle 1 (each cycle is 21 days)
Lowest neutrophil count during chemotherapy cycle 1;, At the end of Cycle 1 (each cycle is 21 days)|Time required for neutrophil count to recover from nadir to above 2.0 × 109/L during chemotherapy cycle 1;, At the end of Cycle 1 (each cycle is 21 days)|Duration of 4th degree neutropenia during cycles 2, 3, and 4 of chemotherapy;, At the end of cycles 2, 3, and 4 (each cycle is 21 days)|Incidence of 3rd or 4th degree neutropenia during cycles 1, 2, 3, and 4 of chemotherapy;, At the end of cycles 1, 2, 3, and 4 (each cycle is 21 days)|Duration of febrile neutropenia (FN) in cycles 1, 2, 3, and 4 of chemotherapy;, At the end of cycles 1, 2, 3, and 4 (each cycle is 21 days)|Incidence of neutropenic fever (FN) during cycles 1, 2, 3, and 4 of chemotherapy;, At the end of cycles 1, 2, 3, and 4 (each cycle is 21 days)|Incidence of infection during cycles 1, 2, 3, and 4 of chemotherapy;, At the end of cycles 1, 2, 3, and 4 (each cycle is 21 days)|Proportion of participants using antibiotics during cycles 1, 2, 3, and 4 of chemotherapy., At the end of cycles 1, 2, 3, and 4 (each cycle is 21 days)
To evaluate the efficacy, safety, and immunogenicity of PEG-G-CSF Injection (Kexing Biopharmaceutical Co., Ltd.) for the prevention of neutropenia after chemotherapy, using the PEG-G-CSF Injection ( Neulasta®, Amgen Europe B.V.) as a positive control.